Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and β2-adrenergic receptors...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Principles of Drug Action01:24

Principles of Drug Action

Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Using a wearable patch to develop a digital monitoring biomarker of inflammation in response to LPS challenge.

Clinical and translational science·2024
Same author

Current Status and Future Directions: The Application of Artificial Intelligence/Machine Learning for Precision Medicine.

Clinical pharmacology and therapeutics·2023
Same author

Quantifying neurologic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosis.

NPJ digital medicine·2019
Same author

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature·2019
Same author

Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature·2018
Same author

CANDI: an R package and Shiny app for annotating radiographs and evaluating computer-aided diagnosis.

Bioinformatics (Oxford, England)·2018
Same journal

Cannabis and Cannabidiol, GLP-1 Receptors, and Autophagy: The Burgeoning Link Between Cognitive Neurodegeneration With Alzheimer's Disease and Metabolic Disorders.

Discovery medicine·2026
Same journal

The Urgent Need to Assess and Prevent the Deposits of Microplastics and Nanoplastics in Our Brain.

Discovery medicine·2025
Same journal

Bridging the Translational Gap: Prioritizing the Spontaneous Canine Osteoarthritis Model for Preclinical Studies.

Discovery medicine·2025
Same journal

Harnessing the Power of Chlorogenic Acid: Inhibiting IL-2-Mediated Treg Upregulation to Combat Post-Traumatic Osteomyelitis.

Discovery medicine·2025
Same journal

The Relationship of <i>MAPK10P</i> Gene Polymorphism With P-Wave Peak Time and P-Wave Dispersion in Elderly Patients With Paroxysmal Atrial Fibrillation.

Discovery medicine·2025
Same journal

Curcumin Attenuates PD-L1-Positive Neutrophil-Induced T-Lymphocyte Apoptosis and Alleviates Lung Injury During Sepsis in Rats.

Discovery medicine·2025
See all related articles

Related Experiment Video

Updated: Jun 17, 2026

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

Therapeutic selectivity and the multi-node drug target.

Joseph Lehar1, Andrew S Krueger, Grant R Zimmermann

  • 1Department of Biomedical Engineering, Boston University, Boston, Massachusetts 02215, USA. jlehar@bu.edu

Discovery Medicine
|December 31, 2009
PubMed
Summary
This summary is machine-generated.

Drug combinations can offer therapeutic benefits but risk synergistic toxicity. This study shows that synergistic drug combinations are context-specific, allowing for the discovery of treatments with improved therapeutic selectivity and reduced side effects.

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Experiment Videos

Last Updated: Jun 17, 2026

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Area of Science:

  • Pharmacology
  • Computational Biology
  • Toxicology

Background:

  • Drug combinations are increasingly used to enhance therapeutic efficacy.
  • Concerns exist regarding synergistic toxicity mirroring therapeutic synergy.
  • Understanding the context-specificity of drug synergy is crucial.

Purpose of the Study:

  • To investigate the context-specificity of synergistic drug combinations.
  • To identify strategies for discovering drug combinations with therapeutic selectivity.
  • To validate the therapeutic relevance of selective synergistic combinations.

Main Methods:

  • Experimental testing of chemical combinations in cell-based disease models.
  • Numerical simulations to analyze synergistic effects.
  • Differential gene expression analysis to understand target behavior.
  • In vivo validation in animal models for an anti-inflammatory combination.

Main Results:

  • Synergistic drug combinations exhibit context-specific effects.
  • Systematic testing in disease models can identify combinations with beneficial therapeutic selectivity.
  • Differential target expression in therapeutic versus toxic cells underlies selective synergy.
  • An anti-inflammatory combination demonstrated therapeutic relevance in animal studies.

Conclusions:

  • The context-specificity of synergistic combinations offers opportunities for therapeutically relevant selectivity.
  • Targeting cooperating biomolecules can lead to improved therapeutic responses with reduced side effects.
  • This approach enhances the potential of drug combinations in medicine.